Genscript Biotech Co. (OTCMKTS:GNNSF – Get Free Report) was the target of a large decline in short interest in June. As of June 30th, there was short interest totaling 2,832,000 shares, a decline of 42.3% from the June 15th total of 4,910,000 shares. Based on an average daily trading volume, of 5 shares, the short-interest ratio is presently 566,400.0 days.
Genscript Biotech Stock Performance
OTCMKTS:GNNSF remained flat at C$1.50 on Friday. Genscript Biotech has a one year low of C$1.30 and a one year high of C$2.42. The stock’s fifty day moving average is C$1.63 and its 200-day moving average is C$1.62.
About Genscript Biotech
GenScript Biotech Corporation is a global contract research, development and manufacturing organization (CDMO) specializing in synthetic biology and biopharmaceutical services. Founded in 2002, the company provides end-to-end solutions that span gene and peptide synthesis, recombinant protein expression, custom antibody discovery and cell line development. GenScript’s integrated platforms support early-stage discovery through to process development, enabling academic institutions, biotech innovators and pharmaceutical companies to accelerate research timelines.
The company’s core offerings include molecular biology services such as DNA construction, gene editing using CRISPR/Cas9 technology and high-throughput peptide libraries.
Featured Stories
- Five stocks we like better than Genscript Biotech
- AST SpaceMobile Stock Sinks as SpaceX Fallout Rattles Space Sector
- Aehr Test Systems Stock Soars on Earnings, Eyes Over 150% Revenue Growth
- TSMC Just Gave AI Chip Bulls Another Reason to Stay Confident
- GE Aerospace Faces a Prove-It Moment in Q2 Earnings
Receive News & Ratings for Genscript Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genscript Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
